Hologic stopped manufacturing the device after reports of serious adverse events in patients who had the markers implanted in breast tissue.

The U.S. Food and Drug Administration has sent a warning letter to Marlborough, Mass.-based medical technology company ...

Hologic Inc. has received a warning letter from the Food and Drug Administration regarding its BioZorb product line, even though the company recalled the devices last year. Hologic Inc. has ...

Marlborough-based medical device manufacturer Hologic has been issued a warning letter from the U.S. Food and Drug Administration concerning its BioZorb Marker, a device originally recalled in March.

FDA issues warning to Hologic, citing manufacturing and safety violations for BioZorb devices. Patient safety risks and reporting failures highlighted ...

Hologic (NASDAQ:HOLX) has received approval from the U.S. Food and Drug Administration (FDA) approval for its new digital cytology system, making it the first FDA-cleared digital cytology platform.

Hologic: Continued Room Amidst Bolt-On M&A Efforts Hologic GAAP EPS of $1.01 beats by $0.18, revenue of $987.9M beats by $11.21M Hologic Q3 2024 Earnings Preview Seeking Alpha’s Quant Rating on ...

Hologic received a warning letter in December from the Food and Drug Administration related to safety concerns with the company’s Biozorb implantable radiographic markers. The FDA found that ...